ALTHEA GROUP HOLDINGS LIMITED (AGH)

The suspension of trading in the securities of Althea Group Holdings Limited will be lifted immediately following the release by AGH of an announcement regarding the outcome of an application to the Federal Court in relation to failures to lodge cleansing notices.

The company announced on 3 February 2025 that it will apply to the ASX for reinstatement of its shares to trading after lodgement of a Cleansing Prospectus and all outstanding ASX forms under the Corporations Act.

The company releases its notice of issue, conversion or payment up of unquoted equity securities.

The company releases its application for quotation of securities.

The company releases a cleansing prospectus for an offer of up to 100 New Shares at an issue price of A$0.10 per new share.

The company releases its results of its annual general meeting.

The company releases its Chair's Address.

The company has received court orders from the Federal Court of Australia regarding its failure to lodge Cleansing Notices under the Corporations Act 2001. The court provided a declaration that offers for sale are valid and relieved the transferring party of civil liability.

The company lodges its Quarterly Activities/Appendix 4C Cash Flow Report.

The company releases a company update. The company requested a voluntary suspension of trading in its shares to apply to the Federal Court for orders related to failures to lodge Cleansing Notices under the Corporations Act 2001. The Federal Court of Australia will hear an application for curative orders, including a declaration that offers for sale are not invalidated and a relief from civil liability.

Peak Processing Solutions has entered a strengthened multiyear manufacturing agreement with BBCCC, Inc., the cannabis subsidiary of The Boston Beer Company. The agreement reinforces Peak's position as BBC's exclusive Canadian manufacturing partner for cannabis beverages through 2026. Enhanced commercial terms improve Peak's cash flow and ensure consistent supply for BBC's cannabis brands, TeaPot and Emerald Hour Cannabis Cocktails. Under the new agreement Peak has committed capacity to BBC of a minimum in excess of 800,000 units for calendar year 2025.

The company issued 31,178,955 shares in excess of its 15% annual placement capacity under ASX Listing Rule 7.1 and 7.1A. The issue was due to a miscalculation of the company's capacity. The ASX advised the company not to issue equity securities without security holder approval until February 2025.

The company announces that its 2024 Annual General Meeting will be held on 31 January 2025, 5:00pm (AEDT) and will be held virtually.

The company has secured $2.0 million in a Loan Notes Placement to cover costs for Peak's Canadian operations, supply chain optimization, and general working capital. The loan notes will be issued as a pure debt instrument at $1.00 each, with the option to convert into ordinary shares at $0.03 per note. The placement is led by Taurus Capital Group Pty Ltd.

The company lodges its 2024 annual report to shareholders.

The securities of Althea Group Holdings Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of AGH, pending the release of an announcement regarding the outcome of an application to the Federal Court in relation to failures to lodge cleansing notices.

The suspension of trading in the securities of Althea Group Holdings Limited will be lifted immediately following the release by AGH of an announcement regarding a capital raise.

AGH is pleased to announce firm commitments received for $1.5 million placement and the launch of a $2.5 million share purchase plan for eligible shareholders. The placement was well supported with strong demand from new and existing institutional and sophisticated investors. Placement and SPP offered at $0.067 per ordinary share. Funds will be utilised to support the launch of new SKUs in the coming months, to continue growing the existing product range and provide general working capital. Funding will enable Althea to accelerate its growth strategy and support the company as it targets cash flow break even and operating profitability in Q3FY23.

The securities of Althea Group Holdings Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of AGH, pending the release of an announcement regarding a capital raise.

The suspension of trading in the securities of Althea Group Holdings Limited will be lifted immediately, following the release by AGH of an announcement regarding an acquisition and capital raising.

Althea agrees to acquire Canadian extraction and contract manufacturing company Peak Processing Solutions, founded by four former senior personnel from Aphria Inc. Althea has opened one of the UK's first cannabis destination clinics in central London and plans to open two further clinics in Q3 CY2019. In July 2019, Althea received a UK import licence for the first shipment of medicinal cannabis products from Australia. Althea is in advanced negotiations regarding a 50/50 joint venture to establish cultivation, extraction and manufacturing (EU GMP) facilities in Portugal. Althea has received commitments for a A$30m capital raising to fund the acquisition and further growth initiatives.

The securities of Althea Group Holdings Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of AGH, pending the release of an announcement regarding an acquisition and capital raising.

The Drug Science Medical Cannabis Working Group, which includes the United Patients Alliance, is launching the UK's first national pilot for medical cannabis. The pilot aims to enrol 20,000 patients before the end of 2021 and will use a real word data patient registry to assess efficacy, safety and patient-reported outcomes in patients prescribed medical cannabis. Althea has been selected from a limited number of medicinal cannabis companies, to supply its range of products to the pilot.

Althea receives its first patient prescription for medicinal cannabis in the UK. Planning permit granted for Althea's Cultivation and Manufacturing facility.

1,000 patients have now been prescribed Althea medicinal cannabis products in Australia. 185 Healthcare Professionals have prescribed Althea medicinal cannabis. Althea is averaging more than 11 new patients per business day, including 227 additional patients in May. Althea has achieved the 1,000 patient milestone five months ahead of schedule.

The company releases its PAC Partners Hong Kong Conference Presentation.

Althea has been granted a Hemp Cultivation Licence allowing the cultivation and processing of low-THC (Hemp) cannabis. Althea has entered into an exclusive agreement with Tissue Culture Australia related to the development of tissue culture protocols for cannabis. The Hemp Cultivation Licence also presents commercial opportunities for Althea in Hemp foods and Isolated-CBD markets including Europe and the USA.

Althea Concierge UK launches successfully with doctors already commencing their first assessments of patients for Althea medical cannabis products. Althea Concierge UK streamlines the prescription process and facilitates patient referrals from primary care doctors to Althea UK specialist prescribers. Althea and Drug Science joint educational meetings to be held in June are oversubscribed, with nearly 300 healthcare professionals registered to attend. Althea sponsored and participated in the recent IOTOD conference in Germany.

The company releases its Securities Dealing Policy.

651 Patients have now been prescribed Althea medicinal cannabis products. 145 Healthcare Professionals have prescribed Althea medicinal cannabis. 140 patients were added between April 4 and April 26 (inclusive), representing 10 new patients per business day. Australia the fastest growing global market in the world (by percentage month-on-month growth). Althea currently recruiting additional staff to capitalise on increased demand.

The company lodges its Appendix 4C - quarterly.

The company provides an investor update.

The company lodges its Half Year Accounts and Report.

The company lodges an Appendix 4D.

Althea has signed a product supply and distribution agreement with Cannvalate, providing Althea with access and support to one of Australia's largest network of medicinal cannabis prescribing clinics. 354 Patients have now been prescribed Althea's medicinal cannabis products. 109 Healthcare Professionals are prescribing Althea's products in Australia.

The company co-launches online portal for free RACGP accredited medical cannabis education.

The company announced expansion and extension of its patient acquisition model into the U.K. through the acquisition of a new UK subsidiary company, Althea MMJ UK Ltd.

The company lodges its Appendix 4C - Quarterly.

Althea has achieved the 300 patient milestone with 86 registered Healthcare Professionals now prescribing Althea products throughout Australia. Althea has also signed an agreement with Cannabis Access Clinics, one of the region's largest medicinal cannabis destination clinic networks, for the education of doctors.

Althea has received its largest medicinal cannabis shipment to date from its major Canadian supplier, Aphria Inc.

The company releases an Investor Presentation - December 2018.

The company releases the results of its meeting.

The company releases the CEO Address to Shareholders.

Althea granted Licence to Export medicinal cannabis. Althea supply to domestic patients continues to grow, with 156 patients and 54 prescribers in its network. Planning permit lodged for ODC approved production facility.

Althea was granted medicinal cannabis Manufacture Licence. Manufacture Licence allows the manufacture of extracts and tinctures of cannabis and cannabis resin, in accordance with relevant manufacture permits. Althea now holds an Import Licence, a Medicinal Cannabis Licence (cultivation and production) and a Manufacture Licence.

The company releases a notice of meeting. The AGM will be held on Friday, 30 November 2018 at 2.00pm (AEDT) at Norton Rose Fulbright Australia Level 15, RACV Tower 485 Bourke Street, Melbourne, Victoria 3000.

The company lodges an Appendix 4C - quarterly.

100 patients were approved for Althea medicinal cannabis products since May 2018. There are 42 doctors prescribing Althea products throughout Australia. 100% approval rate for TGA applications to prescribe Althea products.

Althea signs distribution agreement with major independent cannabis distributor, Health House International. The agreement enhances Althea's national sales footprint and extends coverage to include Western Australia.

listed entity carried for record purposes only